Celltrion Builds on Global Momentum at BIO International Convention with AI Drug Discovery and Next-Gen Biologics
SAN DIEGO — Celltrion, a prominent Korean biosimilar firm, significantly expanded its global partnering initiatives at the BIO International Convention 2026 in San Diego this week. The company prominently showcased its cutting-edge artificial intelligence (AI)-powered drug discovery capabilities and a robust next-generation biologics pipeline, marking a pivotal step in strengthening its strategic alliances.
The BIO International Convention 2026, widely recognized as the world’s premier biopharmaceutical and biotechnology event, attracted an impressive 20,000 participants from over 68 countries, alongside more than 1,600 exhibitors.
Celltrion achieved a new milestone by conducting over 180 business meetings during the four-day convention. This represents the highest number of partnering sessions the company has engaged in since its inaugural participation in the annual event in 2010.
These strategic discussions encompassed a comprehensive spectrum of collaboration opportunities across Celltrion’s diverse business portfolio. Key areas of focus included advanced modalities such as antibody-drug conjugates (ADCs), multispecific antibodies, and innovative AI-enabled drug development technologies.
Celltrion’s researchers and business development executives engaged with prominent global pharmaceutical and biotechnology firms. Their discussions centered on forging potential co-development projects, critical technology partnerships, and strategic manufacturing collaborations, all designed to robustly strengthen Celltrion’s long-term growth pipeline.
Reflecting the burgeoning interest in AI technology, Celltrion prominently showcased its proprietary, self-developed innovations. These included advanced solutions for AI-powered target discovery, sophisticated multispecific antibody design, precise in silico developability assessment, and the Healthcare Intelligence Bank – a cutting-edge, data-driven research platform engineered to significantly accelerate early-stage drug development.
Discussions also extended to manufacturing materials and technologies, with an aim to identify potential partnerships that could enhance production efficiency and bolster technological competitiveness. Celltrion confirmed its intent to advance negotiations with key selected partners following the convention’s conclusion on Thursday.
Beyond the unprecedented number of business meetings, Celltrion’s exhibition booth welcomed over 2,000 visitors across the four-day event, setting another company record for global attendance. Visitors expressed significant interest in Celltrion’s forward-looking AI-driven research strategy and its ambitious future growth roadmap, indicating a notable market shift in attention beyond the company’s well-established biosimilar business.
A Celltrion official commented, “This year’s BIO USA unequivocally underscored Celltrion’s burgeoning recognition on the global stage. The record engagement in business meetings and the high volume of booth visitors signify a heightened interest not only in our established biosimilar portfolio but also in our pivotal next-generation growth engines, encompassing ADCs, multispecific antibodies, and advanced AI-based drug development platforms.”
The official further elaborated that Celltrion is committed to actively advancing the strategic partnership opportunities identified during the convention, aiming to translate this significant investor and industry interest into concrete, tangible business outcomes.
hwkan
